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1366Donor KIR3DL1/3DS1 Gene and Recipient Bw4 KIR
Ligand as Prognostic Markers for Outcome in Unrelated
Hematopoietic Stem Cell Transplantation
Katia Gagne,1,2 Marc Busson,3 Jean-Denis Bignon,1,2 Marie-Lorraine Bale`re-Appert,4
Pascale Loiseau,5 Anne Dormoy,6 Valerie Dubois,7 Pascale Perrier,8 Isabelle Jollet,9
Monique Bois,9 Dominique Masson,10 Agne`s Moine,10 Lena Absi,11 Didier Blaise,12
Dominique Charron,3,5 Colette Raffoux4 on behalf of ARS2000 FRM and FGM groupGiven their antileukemic activity, natural killer (NK) cells can alter the outcome of hematopoietic stem cell
transplantation (HSCT). The physiologic functions of NK cells are regulated by the interaction of killer
immunoglobulin-like receptors (KIR) with specific HLA class I ligands. In the literature, different models
based on HLA class I and/or KIR donor (D)/recipient (R) gene disparities are considered as predictors of
NK cell alloreactivity. In this retrospective and multicentric French study, we analyzed the clinical impact
of the different NK-alloreactivity models in 264 patients who underwent T repleted unrelated HSCT. First,
we did not observe that the ‘‘KIR ligand-ligand’’ model had a significant clinical impact on unrelated HSCT
outcome, whereas the ‘‘missing KIR ligand’’ model had a significant but limited effect on unrelated HSCT,
because only the absence of C1 ligand in patients with myelogenous diseases was associated with a decreased
overall survival (OS) (hazard ratio5 2.17, P5.005). The ‘‘KIR receptor-receptor’’ and the ‘‘KIR receptor-
ligand’’ models seemed the most capable of predicting NK alloreactivity because they had a significant impact
on acute graft-versus-host disease (aGVHD) occurrence, OS, and relapse incidence in D/R unrelated pairs.
In particular, KIR3DL1 gene mismatches in the GVH direction (D1R2) and the D KIR3DL11/3DS11 and
R Bw42 combination were respectively correlated with the lowest OS in HLA identical pairs (HR5 1.99,
P 5.02) and the highest incidence of relapse in HLA nonidentical D/R unrelated pairs (HR5 4.72,
P5.03). Overall, our results suggest a detrimental effect of KIR3DL11/3DS11 donor NK cells transplanted
into HLA-Bw42 patients in the absence of an educational process via KIR3DL1/HLA-Bw4 interactions.
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Hematopoietic stem cell transplantation (HSCT)
is currently used for the treatment of a variety of hema-
tologic malignancies. Whereas the best outcome fol-
lowing HSCT is observed between HLA-identical
siblings, the alternative of using transplants from unre-
lated donors is increasing. When a perfectly HLA
matched donor is unavailable, selection is based on
the best HLA matching considering both class I and
class II loci [1].
The efficacy of allogeneic HSCT remains limited
by several significant complications, such as failure
of the hematopoietic stem cells (HSCs) to engraft,
the occurrence of acute graft-versus-host disease
(aGVHD), relapse, and the susceptibility of patients to
opportunistic infections during the posttransplant
immunodeficiency period. However, a beneficial
graft-versus-leukemia (GVL) response, developed by
donor T lymphocytes or natural killer (NK) cells, could
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depleted HSCT, such as in the case of haploidentical
grafts, alloreactiveNK cells were able to exert thisGVL
effect without causing aGVHD [3].
The physiologic functions of NK cells, such as cell
cytotoxicity, are governed by a balance between inhib-
itory and activating receptors including the killer cell
immunoglobulin-like receptors (KIR), which are spe-
cific for allotypic determinants shared by different
HLA-class I molecules (referred to as KIR ligands)
[4]. Four different inhibitory KIR seem to play a major
role in NK cell alloreactivity because of a more specific
recognition of different HLA class I-encoded ligands.
HLA-Cw allotypes with asparagine at position 80 (C1
ligands) are recognized by KIR2DL2/2DL3, HLA-
Cw allotypes with lysine at position 80 (C2 ligands)
are recognized byKIR2DL1,HLA-A, and -B allotypes
with a polymorphic sequence motif at position 80-83
(Bw4 motif) are targeted by KIR3DL1, and HLA-A3
and -A11 are recognized by KIR3DL2 [5,6]. However,
although the ligands and functions of inhibitory KIR
receptors are well documented, this is not the case
for activating KIR receptors and their ligands, except
for KIR2DS1 [7-9]. In particular, the activating recep-
tor KIR3DS1, which is encoded as an allele of
KIR3DL1, shares more than 97% sequence homology
in its extracellular domain with the KIR3DL1 recep-
tor. However, a functional interaction with HLA-A
or -B allotypes sharing the Bw4 public epitope has
not been demonstrated in vitro [10,11].
KIR genes are located on chromosome 19q13.4.
Until now, 14 functional KIR genes have been charac-
terized [12]. Within the human population, genomic
diversity of the KIR region is achieved on several
levels. First, KIR gene content varies between individ-
uals who can exhibit from 7 to 14 activating and inhib-
itory KIR genes [13]. Based on population studies, 2
major KIR haplotype groups, the A and B haplotypes,
emerged. The A haplotypes have been defined as con-
taining 7 KIR genes, comprising KIR2DS4 as the only
activating KIR gene and the inhibitory KIR3DL3,
-2DL3, -2DL1, -2DL4, -3DL1, and -3DL2 genes.
In contrast, B haplotypes are more variable and are
characterized by the presence of more than 1 activating
KIR genes and the absence of the KIR2DS4 gene [14].
Finally, KIR gene polymorphism is the largest contrib-
utor to the diversity of the KIR region, with multiple
alleles already defined [15].
Because KIR and HLA genes are located on differ-
ent chromosomes (chromosomes 19 and 6, respec-
tively), matching for HLA genes does not generally
result in matched KIR genes in HSCT. Moreover, in
some instances HLA class I mismatching may repre-
sent a KIR-ligand mismatching, leading potentially to
NK alloreactivity. This NK cell alloreactivity appears
particularly beneficial in haploidentical [16] and umbil-
ical cord blood transplantations [17], but its influenceon the outcome of unmanipulated related and unre-
lated HSCT for hematologic malignancies remains
controversial [18,19].
In the literature, different models are considered
for the prediction of NK alloreactivity, referred to as
the ‘‘KIR ligand-ligand’’ model [3], the ‘‘missing KIR
ligand’’ model [20], the ‘‘KIR receptor-receptor’’
model [21], and the ‘‘KIR receptor-ligand’’ model
[22]. Amajority of studies published so far have focused
only on KIR-ligand donor (D)/recipient (R) mis-
matches (‘‘KIR ligand-ligand’’ model) considering the
major HLA class I specificity groups (Bw4, C1, and
C2) recognized by some inhibitoryKIR.These become
potentially beneficial mismatches or ‘‘perfect mis-
matches’’ only if a donorNKgenotype displays the cor-
responding inhibitoryKIRs (ie,KIR2DL1,KIR2DL2/
2DL3, and KIR3DL1), and if the corresponding HLA
class I (KIR-ligandmismatch) is absent in the recipient.
The ‘‘KIR receptor-receptor’’ model takes into
account theKIR genotype of bothD andR, and, in par-
ticular, unravels the clinical impact of inhibitory and
activating KIR gene mismatches. The ‘‘KIR receptor-
ligand’’ model may represent a more predictive model
of potential NK alloreactivity because both the D
KIR genotype and the presence or absence of the cor-
responding R KIR ligand (‘‘missing KIR ligand’’) are
taken into account. Overall, only a combinatory HLA
class I and KIR genetic study should enable a better
evaluation of the real impact of NK alloreactivity in
HSCT, because the NK-KIR repertoire is not only
defined by the combination of inhibitory and activating
KIRgenes (KIR genotypes), but also by theHLAgeno-
type [23-26].
In this retrospective and multicentric French
study, we analyzed the clinical impact of the 4 defined
NK-alloreactivity models in 264 patients who under-
went T repleted unrelated HSCT. Our goal was to
determine whichmodel is themost accurate in predict-
ing aGVHD occurrence, overall survival (OS), and
relapse incidence in HLA identical and nonidentical
D/R pairs. Because we previously showed in a prelimi-
nary report a detrimental effect of KIR3DL1/3DS1
gene disparities on patient survival in unrelated
HSCT [27], we also focused on the clinical relevance
of the D KIR3DL1/3DS1 gene together with the ab-
sence of HLA-Bw4 ligand in recipients assumingly
the follow-up in terms of OS, aGVHD, and relapse.MATERIALS AND METHODS
Patient, Disease, and Transplant Characteristics
The study design was approved by the institutional
review boards of the Societe Franc¸aise de Greffe
de Moelle et de Therapie Cellulaire (SFGM-TC).
D/R unrelated pairs were selected from the 13th Inter-
national Histocompatibility Working Group in
Table 1. Patient, Disease, and Transplant Characteristics of
the 264 Unrelated Pairs Included in the Study
Variable Categories n (%)
Patient
Diagnosis
Malignant diseases 229 (86.7)
Myelogenous diseases 147 (64.0)
No myelogenous diseases 79 (35.0)
Not classified 3 (1.0)
Acute leukemia 138 (52.3)
Chronic myelogenous leukemia 54 (20.5)
Myelodysplastic syndrome 23 (8.7)
Myeloproliferative syndrom 1 (0.4)
Non-Hodgkin lymphoma 11 (4.2)
Hodgkin disease 1 (0.4)
Myeloma 1 (0.4)
Nonmalignant diseases 35 (13.3)
Hemoglobinopathy 1 (0.4)
Aplasia 26 (9.8)
Inborn errors 3 (1.1)
Other 5 (1.9)
Transplant:
Year of transplantation 1993-2000 177 (67.0)
2001-2003 87 (33.0)
Sex of D/R Male/male 90 (34.0)
Female/female 61 (23.0)
Female/male 64 (24.0)
Male/female 49 (19.0)
CMV status of D/R Pos/pos 36 (14.0)
Neg/neg 106 (40.0)
Pos/neg 51 (19.0)
Neg/pos 47 (18.0)
Unknown 24 (9.0)
Preparative regimen TBI/Cy 186 (70.5)
Bu/Cy 37 (14.0)
Source of stem cells unmanipulated bone marrow 264 (100.0)
Acute GVHD incidence Grades II-IV 100 days posttransplant 141 (53.4)
Survival status Alive patients
at 2 years posttransplant
130 (49.2)
Relapse incidence At 30 months
for malignant diseases
55 (24.0)
D indicates donor; R, recipient; CMV, cytomegalovirus; TBI, total body
irradiation; Cy, cyclophosphamide; Bu, busulfan; GVHD, graft-versus-
host disease.
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tersdorf, Seattle, WA), and included complete clinical
and biologic data. Patients who received a unrelated
transplant for the treatment of a hematologic disorder
and who satisfied all of the following criteria were eli-
gible for study: (1) written informed consent obtained
from all patients andDby the participating laboratory/
transplant center permitting inclusion of HLA, KIR,
and clinical data for analysis and reporting; (2) HLA-
A, -B, -Cw, -DRB1, and -DQB1 allele typing available
for both the patient and the D; (3) KIR genotyping
available for both the patient and the D; (4) survival,
aGVHD, and relapse incidence data available on the
patient.
Two hundred sixty-four patients with a median age
of 24.5 years (range: 1-56 years) andwho received anun-
manipulated bonemarrow (BM)graft fromanunrelated
D were included in this analysis. The grafts were per-
formed in 9 French transplant centers between 1993
and 2003 to treat malignant (n5 229) or nonmalignant
diseases (n5 35).Malignant diseases included acute leu-
kemia (AL) (n5 138), chronic myelogenous leukemia
(CML) (n5 54), myelodysplastic syndrome (MDS)
(n5 23), myeloproliferative syndrome (n5 1), non-
Hodgkin lymphoma (NHL) (n5 11), Hogdkin disease
(HD) (n5 1), and myeloma (n5 1). All patients were
prepared for transplantation with the use of myeloabla-
tive (MA) conditioning regimens. The source of grafted
cells for all patients was BM without T cell depletion.
Theminimal clinical information collected for each
patient was aGVHD (date of onset and grade), date of
the last visit (alive/deceased status), and relapse. The
severity of aGVHD was graded according to interna-
tional criteria [28,29]. All patients were considered
eligible for aGVHD evaluation at day 11 after trans-
plantation. The overall incidence of grade II-IV
aGVHD and severe aGVHD (grade III-IV) at 100
days posttransplant was 53.4% (n5 141) and 25.8%
(n5 68), respectively. At 2 years posttransplant, 130
patients had survived (49.2%) and134haddied.Finally,
55 of 229 (24%) patients suffering frommalignant dis-
eases had relapsed at 30 months posttransplant.
The main patient, disease, and transplant charac-
teristics are described in Table 1.
Genomic DNA Extraction
Anticoagulant peripheral blood (PB) samples were
obtained from all patients before initiating the condition-
ing regimen and on the day of transplantation from all
Ds. Peripheral blood mononuclear cells (PBMC) from
patients and Ds were used as a source of genomic DNA
extracted using a classical salting-out method.
HLA Class I and Class II Genotyping
High-resolution typing for HLA-A, -B, -Cw,
-DRB1, and -DQB1 was performed using PCR-SSPamplification kits (OneLambda, Inc., Canoga Park,
CA, or Genovision, West Chester, PA, or Dynal, Invi-
trogen Cergy-Pontoise, France) or by sequence-based
typing as previously described [30]. In all cases, an un-
ambiguous 4-digit typing was obtained.KIR Genotyping
All patients and Ds were typed for the presence or
absence of 14 functional KIR genes (KIR2DL1,
2DL2, 2DL3, 2DL4, 2DL5, 3DL1, 3DL2, 3DL3,
2DS1, 2DS2, 2DS3, 2DS4, 2DS5, and 3DS1) using 2
PCR-SSP methods as previously described [27]. D/R
KIR gene disparities were evaluated in both directions
(D2R1 and D1R), in the HVG direction (D2R1
only), and in the GVH direction (D1R2 only).
The assignment of KIR genotypes was based on
the reaction pattern observed compared to those asso-
ciated with published KIR gene sequences. The KIR
genotypes (AA, AB, and BB) were determined as ini-
tially defined by Uhrberg et al. [14].
Table 2. HLA, KIR-Ligand, KIR, and KIR/KIR Ligand Gene
Mismatching Characteristics of the 264 Unrelated Pairs
Included in the Study
Variable Categories n (%)
D/R HLA identity*
10/10 matched 164 (62.1)
not 10/10 matched 100 (37.9)
D/R KIR ligand mismatching status†
Bw4Bw6 / Bw6Bw6 2 (0.7)
Bw4Bw4 / Bw4Bw6 2 (0.7)
Bw6Bw6 / Bw4Bw6 2 (0.7)
C1C2 / C1C1 7 (2.6)
C1C2 / C2C2 9 (3.4)
C1C1 / C1C2 16 (6.0)
C2C2 / C1C2 4 (1.5)
Missing KIR ligand in patients‡
At least one KIR ligand absent:
Bw4 group absent 81 (30.6)
C1 group absent 40 (15.2)
C2 group absent 95 (36.0)
D/R KIR gene mismatching status§
2DL1 mismatched 23 (8.7)
2DL2 mismatched 124 (47.0)
2DL3 mismatched 48 (18)
2DL5 mismatched 77 (29.0)
3DL1 mismatched 36 (13.6)
2DS1 mismatched 121 (45.8)
2DS2 mismatched 126 (47.7)
2DS3 mismatched 101 (38.3)
2DS4 mismatched 33 (12.5)
2DS5 mismatched 96 (36.4)
3DS1 mismatched 127 (48.1)
D/R KIR genotype mismatching status¶
AA / AB 34 (12.9)
AB / AA 43 (16.3)
BB / AB 9 (3.4)
AB / BB 8 (3.0)
BB / AA 9 (3.4)
AA / BB 1 (0.4)
D inhibitory KIR/R KIR ligand matching statust
At least, one KIR/KIR ligand mismatch:
D 2DL1+/R C22 89 (33.8)
D 2DL2+ and/or 2DL3+/R C12 38 (14.3)
D 3DL1+/R Bw42 73 (27.6)
*High resolution typing.
D indicates donor; R, recipient.
10/10 matched: D/R pairs are identical for HLA-A, -B, -Cw, -DRB1,
-DQB1 at allelic level.
†Bw4 group: HLA-A23, A24, A32, and HLA-B molecules with amino
acids TALR, IALR, TPLR, or TLLR80-83; ligand for KIR3DL1.
C1 group: HLA-Cw molecules with amino-acid Asn80; ligand for
KIR2DL2/2DL3.
C2 group: HLA-Cw molecules with amino-acid Lys80; ligand for
KIR2DL1/2DS1.
All D/R pairs were divided into Bw4, Bw6, C1, or C2 groups depending
on their HLA-A, -B, and -Cw typings.
‡Bw4 group: HLA-A23, A24, A32, and HLA-B molecules with amino
acids TALR, IALR, TPLR, or TLLR80-83.
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Differences in categoric variables between 2
groups were evaluated by chi-square analysis (with
Yates correction if needed or Fisher tests in case of lim-
ited series). Univariate and multivariate proportional
hazard regression models were used to identify inde-
pendent risk factors of death bymeans of log-rank tests
and Cox proportional hazard models, respectively.
The univariate Kaplan-Meier analysis was used to
describe risk factors for death. Cumulative incidence
using the competing risk method as described by
Fine and Gray [31] was used to assess factors affecting
the prognosis of aGVHD and relapse with death or
death without relapse for relapse analysis as a compet-
ing event. Cox regression analysis was also used for the
multivariate analysis of risk factors for death [32]. A
stepwise backward procedure was used to construct
a set of independent predictors of each end point. All
predictors achieving a P-value below .15 were consid-
ered and sequentially removed if the P-value in the
multiple model was above .05. The proportional haz-
ard assumption was checked by graphical method.
All tests were 2 sided, with the type I error rate fixed
at .05. Statistical analyses were performed with SPSS
15 software, Stata 10 s and the R package ‘‘cmprsk’’
for competing risks. Numbers of cases at risk were
given in parentheses in the Tables 3 and 4.
Graft, patient, and donor characteristics—other
than D/R HLA class I (KIR ligands) and/or KIR
gene disparities—such as date of transplantation, pa-
thologies (malignant versus nonmalignant diseases,
myelogenous versus myelogenous diseases), condi-
tioning regimen, D/R age, sex matching, and CMV se-
rology that could potentially influence aGVHD
occurrence, OS, relapse incidence, were also evaluated
in all D/R pairs combined and then separately in HLA
identical and nonidentical pairs. Those that were
found significantly associated with aGVHD (patholo-
gies and D/R cytomegalovirus (CMV) status) or with
OS (D/R HLA class I and class II matching, D/R
CMV status, and D/R sex combination, period of
graft) by univariate analysis (Table 3) were included
in the multivariate analysis with variables of interest
for this study (Table 4). None of the previous charac-
teristics was found significantly associated with relapse
in our series by univariate method.C1 group: HLA-Cw molecules with amino-acid Asn80.
C2 group: HLA-Cw molecules with amino-acid Lys80.
§Presence or absence of functional KIR genes was evaluated by low-res-
olution PCR-SSP in each D/R pair. KIR gene mismatches were analyzed
in both directions (D2R+, D+R2). KIR2DL4, 3DL2, and 3DL3 were not
included because they are always present in D/R pairs.
¶KIR genotype AA: Only KIR2DS4 is present as activating KIR genes.
KIR genotype BB: All activating KIR genes may be present except
KIR2DS4.
KIRgenotypeAB:KIR2DS4 and otherKIR activating genesmay be present.
tPresence of inhibitory KIR2DL1, 2DL2/2DL3, or 3DL1 genes in the
donor and absence of the corresponding KIR ligand (C2, C1, or Bw4)
in the patient were evaluated in each D/R pair.RESULTS
Impact of Donor/Recipient KIR Ligand
Disparities According to the ‘‘Ligand-Ligand’’
Model on Unrelated HSCT Outcome
In this French cohort (n5 264), 164 patients
(62.1%) received transplants from fully 10/10 HLA
matched Ds (ie, identical allele typing for HLA-A,
-B, -Cw, -DRB1, and -DQB1 loci), whereas 100
Table 3. Significant Factors Influencing Acute GVHD Incidence, Overall Survival, and Relapse Incidence in Donor/Recipient Pairs
of Unrelated HSCT
All pairs
(n5 264) P
HLA Identical
Pairs (n5 164) P
HLA nonidentical
pairs (n5 100) P
Outcome and significant
factors, % (n)
Acute GVHD:*
D/R KIR2DL5 mismatched
versus matched
43% (26) versus 21% (93) .01†,‡
D/R KIR2DS1 mismatched
versus matched
65% (49) versus 45% (51) .02
D/R KIR2DS3 mismatched
versus matched
14% (44) versus 28% (220) .05†,‡ 12% (61) versus 29% (103) .01†
D KIR genotype AA
versus AB, BB
40% (15) versus 16% (76) .03†,§
At least 1 KIR/KIR ligand
mismatch versus 0
24% (231) versus 41% (32) .03†
D KIR2DL222DL3+2DS22/
R C12 versus R C1+
83% (12) versus 55% (99) .04
Other factors
Myelogenous versus
nonmyelogenous diseases
47% (147) versus 68% (80) .007
D/R CMV+ versus other
combinations
70% (38) versus 50% (208) .01
Malignant versus
nonmalignant diseases
56% (140) versus 29% (21) .03
Overall survival:¶
Patients C2C2+ versus
patients C1C1+, C1C2+
19% (21) versus 54% (126) .005§
D/R KIR2DS1 mismatched
versus matched
43% (47) versus 63% (44) .03§
D/R KIR3DL1 mismatched
versus matched
19% (36) versus 46% (228) .004 23% (21) versus 53% (143) .002 0% (9) versus 35% (91) .01t
D/R KIR3DS1 mismatched
versus matched
28% (37) versus 55% (126) .03t
Other factors
D/R HLA nonidentical
versus identical
31% (100) versus 49% (164) .02
Grafts 1993-2000
versus 2001-2003
34% (177) versus 59% (87) .001 25% (79)
versus 61% (21)
.01
D/R CMV+ versus other
combinations
23% (38) versus 46% (208) .01 28% (31) versus 54% (152) .0007
Grafts F/F versus
other combinations
56% (61) versus 37% (203) .03 74% (43) versus 42% (152) .005
Relapse:**
D/R KIR2DS3 mismatched
versus matched
32% (31) versus 12% (109) .02t
D/R KIR2DS4 mismatched
versus matched
0% (27) versus 21% (202) .05
D KIR3DL1+/ R Bw42
versus R Bw4+
28% (66) versus 18% (143) .04
D KIR3DS1+/ R Bw42
versus R Bw4+
37% (26) versus 16% (72) .02 33% (14) versus 8% (41) .02
D KIR3DL1+, 3DS1+/ R
Bw42 versus R Bw4+
43% (22) versus 20% (60) .004 40% (11) versus 11% (33) .03 44% (11)
versus 29% (27)
.05
D indicates donor; R, recipient; F, female; CMV, cytomegalovirus; GVHD, graft-versus-host disease.
*Acute GVHD: cumulative incidence at 100 days (death as competing risk), grades II-IV.
†Severe acute GVHD: cumulative incidence at 100 days (death as competing risk), grades III-IV.
‡Mismatches D2R+.
§Myelogenous diseases group.
¶Overall survival at 2 years.
tMismatches D+R2.
**Relapse: cumulative incidence at 30 months (death as competing risk) for malignant diseases group.
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lele-mismatched D (Table 2). To evaluate HLA class
I mismatching in terms of KIR-ligand mismatch sta-
tus, D/R pairs were further divided into Bw4, Bw6,
C1, or C2 groups depending on their HLA-A, -B,
and -Cw typings. In the entire cohort (n5 264), con-sidering the Bw4 and Bw6 status, 6 D/R pairs (2.3%)
were mismatched for the KIR ligand in both directions
and only 2D/R pairs were mismatched in theGVH di-
rection (Table 2). In the entire cohort (n5 264), con-
sidering the C1 and the C2 status, 36 D/R pairs
(13.6%) were KIR ligand mismatched in both
Table 4. Significant Factors Influencing Acute GVHD Incidence, Overall Survival, and Relapse Incidence in Donor/Recipient Pairs
of Unrelated HSCT (Multivariate Analysis)
All pairs
(n5 264) P
HLA identical pairs
(n5 164) P
HLA nonidentical
pairs (n5 100) P
Outcome and significant factors, HR (95%CI)
Acute GVHD*
D/R KIR2DL5 mismatched versus matched 2.63 (1.18-5.55) .02†,‡
D/R KIR2DS1 mismatched versus matched 1.88 (1.07-3.29) .03
D/R KIR2DS3 mismatched versus matched 0.59 (0.37-0.95) .03
D/R KIR2DS3 mismatched versus matched 0.25 (0.09-0.75) .01†
Other factors
Myelogenous versus nonmyelogenous diseases 0.57 (0.38-0.84) .004
D/R CMV+ versus other combinations 1.65 (1.02-2.68) .04
Malignant versus nonmalignant diseases 2.67 (1.17-6.23) .02
Overall survival§
Patient C2C2+ versus patients C1C1+, C1C2+ 2.17 (1.26-3.75) .005¶
D/R KIR3DL1 mismatched versus matched 1.94 (1.28-2.94) .002 1.99 (1.14-3.51) .02
Other factors
D/R HLA nonidentical versus identical 1.40 (1.00-1.95) .05
D/R CMV+ versus other combinations 1.57 (1.03-2.41) .04
Grafts F/F versus other combinations 0.58 (0.37-0.89) .02 0.45 (0.23-0.89) .02
Relapset
D KIR3DL1+, 3DS1+/ R Bw42 versus R Bw4+ 5.96 (2.13-16.67) .001 4.72 (1.17-19.10) .03
D indicates donor; R, recipient; F, female; CMV, cytomegalovirus; GVHD, graft-versus-host-disease.
Only factors P < .05 are included. Data are hazard ratio and 95% confidence interval.
*Acute GVHD: cumulative incidence at 100 days (death as competing risk), grades II-IV.
†Severe acute GVHD: cumulative incidence at 100 days (death as competing risk), grades III-IV.
‡Mismatches D-R+.
§Overall survival at 2 years.
¶Myelogenous diseases group.
tRelapse: cumulative incidence at 30 months (death as competing risk) for malignant diseases group.
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matched in the GVH direction (Table 2). No signifi-
cant differences were observed in the incidence of
aGVHD, OS, and relapse incidence between KIR li-
gand matched versus KIR ligand mismatched D/R
pairs in both directions and in theGVHdirection only.
Impact of ‘‘Missing KIR Ligands’’ in Patients on
Unrelated HSCT Outcome
Taking into account both the Bw4 and C1 and C2
groups, 167 patients (63.3%) had at least 1 KIR ligand
absent (Table 2). No significant differences were
observed in the incidence of aGVHD, OS, and relapse
incidence related to the absence of the HLA-Bw4
ligands in patients (data not shown). In contrast, the
absence of HLA-CwAsp80 (C1) molecules in R had
a significant impact on unrelated HSCT in this cohort
because univariate analysis showed that C2C21
(C12, n5 21) patients with myelogenous diseases had
a lowerOS compared toC1C11 andC1C21 recipients
(C11, n5 126) (19% versus 54% at 2 years, P5 .005;
Table 3). Multivariate Cox analysis also revealed a
decreased OS of C2C21 (C12) patients with myeloge-
nous diseases (hazard ratio [HR]5 2.17, P5 .005;
Table 4). A lack of the C1 ligand in R no longer had a
significant effect on OS when HLA identical and non-
identical pairs were analyzed separately (data not
shown). No significant differences were observed in
terms of the incidence of aGVHD, or relapse relatedto the absence of the HLA-C1 ligands in patients
(data not shown).
Impact of D/R KIR Gene Disparities According
to the ‘‘Receptor-Receptor’’ Model on Unrelated
HSCT Outcome
Based on the presence or absence of individual KIR
genes in each D/R pair, inhibitory and activating KIR
gene disparities were evaluated (Table 2). The mis-
matching rate in both directions (R1D2 or D2R1)
for KIR2DL1, 2DL2, 2DL3, 2DL5, and 3DL1 was
8.7%, 47%, 18%, 29%, and 13.6%, respectively. Con-
cerning the activatingKIR genes, themismatching rate
in both directions for KIR2DS1, 2DS2, 2DS3, 2DS4,
2DS5, and 3DS1 was 45.8%, 47.7%, 38.3%, 12.5%,
36.4%, and 48.1%, respectively. In terms of KIR geno-
types, 104 D/R pairs (39%) were mismatched for AA,
AB, or BB genotypes (Table 2). Univariate and multi-
variate analysis showed that mismatching for the
KIR2DL5 gene only in the HVG direction (D2R1)
was deleterious in HLA identical pairs by increasing
severe aGVHD incidence (43% versus 21%, P5 .01;
Table 3; HR5 2.63, P5 .02; Table 4). D/R KIR2DS1
genemismatches in both directions were deleterious in
HLA identical pairs for patients with myelogenous
diseases, by decreasing OS (43% versus 63%, P5 .03;
Table 3) and in HLA nonidentical pairs by increasing
aGVHD incidence (65% versus 45%, P5 .02; Table
3; HR51.88, P5 .03; Table 4). In contrast, D/R
Figure 1. Impact of KIR3DL1/3DS1 gene disparities on patient survival
in unrelated HSCT. (A) Cumulative survival of patients who received
transplants matched for KIR3DL1 (n5 143, R1D1 and R2D2) was
compared with that of patients who received KIR3DL1 mismatched
transplants in both directions (n5 21, R1D2 and R2D1). Unrelated
D/R pairs were identical at the allelic level for HLA-A, -B, -Cw,
-DRB1, and -DQB1 (n5 164). (B) Cumulative survival of patients who
received transplants matched for KIR3DS1 (R1D1, R2D2) or mis-
matched in the HVG direction (R1D2) (n5 126) was compared with
that of patients who received KIR3DS1 mismatched transplants in the
GVH direction (n5 37, R2D1). Unrelated D/R pairs were identical at
the allelic level for HLA-A, -B, -Cw, -DRB1, and -DQB1 (n5 164). A
value of P # .05 was considered as statistically significant.
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incidence both in all pairs combined (D2R1) and in
HLA identical pairs (14% versus 28%, P5 .05 and
12% versus 29%, P 5 .01 respectively; Table 3). This
beneficial effect of D/RKIR2DS3 genemismatches re-
mained significant bymultivariate analysis restricted to
HLA identical pairs by decreasing both aGVHDII-IV
and severe aGVHDIII-IV (HR5 0.59, P5 .03 and
HR5 .25, P5 .01 respectively; Table 4). Conversely,
D/R KIR2DS3 mismatches in the GVH direction
(D1R2) increased relapse incidence in HLA identical
pairs restricted to malignant diseases (32% versus
12%, P5 .02; Table 3). D/R KIR2DS4 gene mis-
matches in both directions had a beneficial effect on
relapse incidence in all pairs restricted for malignant
diseases (0% versus 21%, P5 .05; Table 3), but this
effect was no longer significant when D/R pairs were
divided into HLA identical and nonidentical groups.
Among these KIR genes, KIR3DL1 appeared as a
‘‘keymarker’’ becauseD/RKIR3DL1genemismatches
decreased OS in all pairs (19% versus 46%, P5 .004;
Table 3), in HLA identical pairs (23% versus 53%,
P5 .002; Table 3 and Figure 1A), as well as in HLA
nonidentical pairs (0% versus 35%, P5 .01, D1R2;
Table 3).Multivariate analysis also confirmed the dele-
terious effect of D/R KIR3DL1 gene mismatching on
OS in all D/R pairs combined (HR5 1.94, P5 .002;
Table 4) and in D/R HLA identical pairs (HR5 1.99,
P5 .02; Table 4). Surprisingly, KIR3DS1, the activat-
ing counterpart of KIR3DL1, but which segregates as
an allele, also had a deleterious effect, because HLA
identical D/R pairs mismatched for KIR3DS1 in the
GVHdirection (D1R2) had a lower survival compared
to KIR3DS1-matched D/R pairs (28% versus 55%,
P5 .03; Table 3 and Figure 1B). D/R KIR2DL1,
2DL2, 2DL3, 2DS2, and 2DS5 gene mismatches had
no significant impact on unrelated HSCT outcome in
this particular cohort (data not shown).
Patients with myelogenous diseases receiving
grafts from AA KIR genotype donors (n5 15) devel-
oped a higher incidence of severe aGVHD compared
to patients receiving grafts from AB or BB KIR geno-
type donors restricted to D/R HLA identical pairs
(40% versus 16%, P5 .03; Table 3).Impact of Donor KIR Genes and Recipient HLA
Class I Ligand Disparities According to the
‘‘Receptor-Ligand’’ Model on Unrelated HSCT
Outcome
A potential correlation between the presence of in-
hibitory KIR2DL1, KIR2DL2/2DL3, or KIR3DL1
genes in the D and the absence of the corresponding
KIR ligand in the R was next investigated. Overall,
200D/Rpairs had at least 1KIR/KIR ligand-mismatch
(Table 2). The severe aGVHD incidence was signifi-
cantly decreased in D/R pairs with at least 1 KIR/KIR ligand mismatch compared to D/R pairs without
KIR/KIR ligand mismatch (24% versus 41%,
P5 .03; Table 3). However, C12 patients grafted
with a KIR2DL22/2DL31/2DS22D showed a higher
incidence of aGVHD (grades II-IV) compared to C11
patients (83% versus 55%, P5 .04; Table 3), suggest-
ing the importance of some activating KIR genes in
the donor. KIR3DL1/Bw4 or KIR3DL1/3DS1/Bw4
ligand mismatching had no significant effect on
aGVHD incidence (data not shown). Although not
significant, Bw42 patients receiving grafts from
KIR3DL11/3DS11 Ds displayed a lower OS both in
HLA identical (37% versus 50%, P5 .56) and in
HLA nonidentical pairs (19% versus 32%, P5 .16,
data not shown). Interestingly, the deleterious effect
of the donor KIR3DL11 or KIR3DS11 gene was rele-
vant for relapse incidence in Bw42 patients withmalig-
nant diseases. Indeed, Bw42 patients receiving grafts
from KIR3DL11 Ds or from KIR3DS11 Ds showed
a higher incidence of relapse compared to Bw41
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16%,P5 .02, respectively;Table 3) when allD/Rpairs
were taken into account. When restricted to HLA
identicalD/Rpairs, only Bw42patients withmalignant
diseases receiving a graft from KIR3DS11 donors ex-
hibited a significantly higher incidence of relapse com-
pared to Bw41 patients (33% versus 8%, P5 .02;
Table 3 and Figure 2A). This effect was reinforced byFigure 2. Impact of donorKIR3DL1/3DS1 and recipient Bw4 ligand dis-
parities on relapse incidence in unrelated HSCT. (A) Cumulative inci-
dence of relapse in HLA-Bw41 patients with malignant diseases grafted
with a KIR3DS11 donor (n5 41) was compared to that in HLA-Bw42
patients receiving a graft from a KIR3DS11 donor (n5 14). Unrelated
D/R pairs were HLA identical at the allelic level for HLA-A, -B, -Cw,
-DRB1, and -DQB1. (B) Cumulative incidence of relapse in HLA-Bw41
patients with malignant diseases receiving a graft from a KIR3DL11/
3DS11 donor (n5 33) was compared to that in HLA-Bw42 patients
receiving a graft from a KIR3DL11/3DS11 donor (n5 11). Unrelated
D/R pairs were HLA identical at allelic level for HLA-A, -B, -Cw,
-DRB1, and -DQB1. (C) Cumulative incidence of relapse in HLA-Bw41
patients with malignant diseases receiving a graft from a KIR3DL11/
3DS11 donor (n5 27) was compared to that in HLA-Bw42 patients
receiving a graft from a KIR3DL11/3DS11 donor (n5 11). Unrelated
D/R pairs were HLA mismatched with at least 1 allele mismatch for
HLA-A, -B, -Cw, -DRB1, or -DQB1 loci. A value of p # .05 was consid-
ered as statistically significant. The Bw4 status was evaluated depending
on HLA-A (A23, A24, A32) and -B allelic typing of the recipient.taking into account both the presence of KIR3DL1
and the KIR3DS1 gene in theD, because the incidence
of relapse increased to 43% forBw42patients receiving
grafts from KIR3DL11/3DS11 Ds compared to 20%
for Bw41 patients when all D/R pairs were considered
(P5 .004; Table 3; HR5 5.96, P5 .001; Table 4).
This deleterious combination (D: KIR3DL11/
3DS11 and R Bw42) had a significant impact both in
HLA identical pairs (40% versus 11%, P5 .03; Table
3 and Figure 2B) and in HLA nonidentical pairs
(44% versus 29%, P5 .05; Table 3 and Figure 2C;
HR5 4.72, P5 .03; Table 4).DISCUSSION
In this retrospective, multicentric study, we
analyzed the clinical impact of the 4 defined NK-
alloreactivity models in 264 patients who underwent
T repleted unrelated HSCT. First, we did not observe
that the ‘‘KIR ligand-ligand’’ model had a significant
clinical impact on unrelated HSCT outcome. How-
ever, the effect of KIR ligand mismatching (Bw4, C1,
or C2) in both directions and in the GVH direction
(D1R2) was evaluated in few KIR-ligand mismatched
pairs compared to the KIR ligand matched pairs.
This observation is probably also related to the absence
ofT cell depletion in the grafts or to the heterogeneous
diseases included in this study, because the beneficial
effect of KIR ligand disparities in the GVH direction
was initially described in haploidentical HSCT with
extensive T cell depletion and was restricted to acute
myelogenous leukemia (AML) patients [3]. Second,
we observed that the ‘‘missing KIR ligand’’ model
had a significant but limited effect on unrelated
HSCT. Indeed, only the absence of C1 ligand in pa-
tients was associated with a decreased OS when HLA
identical and HLA nonidentical D/R pairs were com-
bined. However, a lack of C1 ligand in patients no lon-
ger had a significant effect on OS when HLA identical
and nonidentical pairs were analysed separately or
when the presence of the D KIR2DS2 gene was taken
into account as initially reported in HLA-identical sib-
lingHSCT for myelogenous leukemia [33]. Moreover,
no effect of missing KIR ligand on aGVHD or relapse
incidence was observed, in contrast to previous studies
[20,34]. Third, we observed that the ‘‘KIR receptor-
receptor’’ model influenced the outcome of both
HLA identical and HLA nonidentical unrelated
HSCT. In particular, multivariate analyses showed
that D/R KIR2DL5 or KIR2DS1 mismatches are del-
eterious by increasing aGVHD incidence in HLA
identical and HLA nonidentical pairs, respectively. In
contrast, D/R KIR2DS3 mismatches had a beneficial
effect by decreasing aGVHD in HLA identical pairs.
The D KIR3DL1 gene appeared to be a risk factor,
especially in HLA identical D/R pairs, because
1374 Biol Blood Marrow Transplant 15:1366-1375, 2009K. Gagne et al.mismatches in the GVH direction (D1R2) signifi-
cantly decreased OS. This deleterious effect of the
donor KIR3DL1 gene was reinforced taking into ac-
count the presence of its activating counterpart (ie,
KIR3DS1). Our present findings concerning the dele-
terious effects of the D/R KIR gene mismatches are
consistent with the literature because inhibitory and
mainly activating KIR gene disparities in the GVH
direction (D1R2) have been correlated with a higher
incidence of aGVHD, a higher incidence of relapse,
or a lower OS in unrelated HSCT pairs [21,35-38].
The presence of particular activating KIR genes in the
D (ie, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS5,
KIR3DS1) seems deleterious both in Caucasoid
[21,35-38] and in non-Caucasoid populations [39].
Two recent studies have reported a deleterious effect
of the D KIR3DS1 gene [37] or the R KIR2DS3 gene
[40] on relapse incidence in unrelated HSCT. Surpris-
ingly, in terms of KIR haplotypes, the presence of
a high number of activating KIR genes in the D (AB
and BB vs. AA haplotypes) had no significant effect
on OS or relapse incidence, but decreased aGVHD in
our cohort. This beneficial effect of D KIR B haplo-
types has also been demonstrated in unrelated HSCT
outcome inKoreanpatients, by decreasing aGVHDin-
cidence [41], and recently in a large cohort of AML pa-
tients, by increasing OS [42].
Finally, we observed that the ‘‘KIR receptor-
ligand’’ model influences the outcome of both HLA
identical and nonidentical D/R unrelated pairs. In par-
ticular, we showed for the first time that the genetic
combination of D KIR3DL11/3DS11 and R Bw42
correlated with the highest incidence of relapse in
both HLA identical and HLA nonidentical D/R
unrelated pairs compared to the combination D
KIR3DL11/3DS11 and RBw41. Until now, few stud-
ies have investigated the impact of the ‘‘KIR receptor-
ligand’’ model on unrelated HSCT outcome and no
relevant combination between the presence of particu-
lar donorKIRgenes and the absence of a corresponding
KIR ligand in the R has been identified [37,39,42-44].
However, the studies published so far have focused
only on limited KIR/KIR ligand interactions (mainly
KIR2DL1/C2, KIR2DL2/2DL3/C1), or limited KIR
ligands (only HLA-B Bw41 molecules considered as
KIR3DL1 ligands). In this study, we demonstrated
for the first time that the presence of the D
KIR3DL11/3DS11 gene and the absence of the corre-
spondingRBw4 ligand (bothHLA-A andHLA-Bmol-
ecules considered) correlates with a higher incidence of
relapse, whereas the presence of the D KIR3DL11/
3DS11 gene and the R Bw4 ligand correlates with
a lower incidence of relapse. These immunogenetic
data suggest a potential beneficial D KIR3DL11/
3DS11 NK cell alloreactivity against R Bw41 leuke-
mic cells, leading to a decreased incidence of relapse
(potential GVL effect), as already suggested by Foleyet al. [45]. However, the expression level of the
KIR3DL1 and KIR3DS1 receptors at the surface of
D NK cells should be measured because the D
KIR3DL11/3DS11 NK repertoire could differ de-
pending on the presence or absence of autologous
KIR ligand (Bw4) and on KIR3DL1 allelic and/or pro-
moter polymorphism [46-48].
Overall, our results show that the ‘‘KIR receptor-
receptor’’ and ‘‘KIR receptor-ligand’’ models seemed
the most suitable to predict NK alloreactivity, because
they had a significant impact on aGVHD occurrence,
OS, and relapse incidence in HLA identical and in
HLA nonidentical unrelated D/R pairs. In particular,
our results suggest a detrimental effect of D
KIR3DL11/3DS11 D NK cells transplanted into
HLA-Bw42 patients in the absence of an education
process via KIR3DL1/HLA-Bw4 interactions. These
results have to be confirmed on independent homoge-
nous series taking into account other important param-
eters that may also contribute to HSCT outcome such
asGVHDprophylaxis regimen, disease status, or high-
versus low-risk hematologic malignancies.ACKNOWLEDGMENTS
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